Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Journal Information
Full Title: Br J Cancer
Abbreviation: Br J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests D. S. Zebic reports honoraria from Merck. A. Tjokrowidjaja reports research funding (institution) from AZ, support for attending meetings from GSK. K. E. Francis reports funding from BMS, support for attending educational meeting. M. Friedlander reports consulting fees from Novartis, AstraZeneca, MSD, GSK; honoraria from AstraZeneca, GSK, MSD; grants (institution) from AstraZeneca, Novartis, Beigene; participation on a Data Safety Monitoring Board or Advisory Board for AGITG. V. Gebski reports no conflict of interest. A. Lortholary reports participation on Advisory Board for AstraZeneca, MSD Tesaro; honoraria from Clovis Oncology, Roche; congress participation for Novartis, Pfizer, MAD, Lilly, Roche; member of CS3 sein UNICANCER. F. Joly reports participation on Advisory Board for GSK, AstraZeneca, Clovic, Seagen, Janssen, ESAI, Bayer, Viatris, MSD, Ipsen, Amgen, Astellas; honoraria from GSK, Bayer, ESAI, MSD; research funding (personal) from AstraZeneca, GSK; participation member for ASCO, GCIG; congress travel fees from GSK, MSD, ESAI, Ipsen. A. Hasenburg reports honoraria from AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup GmbH, Tesaro Bio Germany GmbH; participation on Advisory Board for AstraZeneca, GSK, LEO Pharma, PharmaMar, Promedicis GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH, MSD Sharp&Dohme GmbH. M. Mirza reports participation Data Safety Monitoring Board or Advisory Board for Astra Zeneca, Biocad, GSK, Karyopharm, Merck, Roche, Zailab; honoraria from Astra Zeneca, GSK; research funding (institution) from Apexigen, AstraZeneca, Deciphera (trial chair), GSK, and Ultimovacs; and personal financial interest in Karyopharm (stocks/shares, member of Board of Directors). U. Denison reports no conflict of interest. S. C. Cecere reports honoraria from AstraZeneca, MSD, Pharmamar. A. Ferrero reports honoraria from AstraZeneca, MSD, GlaxoSmithKline, Clovis; participation Data Safety Monitoring Board or Advisory Board for AstraZeneca, MSD. E. Pujade-Lauraine reports honoraria (personal) from AstraZeneca, GSK, Agenus; grants (institution) from AstraZeneca, Merck; participation on Advisory Board or Data Safety Monitoring Board for Incyte, Roche, Pfizer; and is an employee of ARCAGY GINECO research. C.K. Lee reports honoraria from AstraZeneca, Roche, Amgen, GSK, Merck KGA, Novartis, Pfizer, Janssen; grants (institution) from AstraZeneca, Roche, Amgen, Merck KGA; support for attending meetings from AstraZeneca."
"Funding Open Access funding enabled and organized by CAUL and its Member Institutions."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025